ESMO 2022 | IDE397: a novel MAT2A inhibitor in patients with solid tumors harboring MTAP deletions

Melissa Johnson, MD, Sarah Cannon Research Institute, Nashville, TN, talks on the trial design and rationale of an open-label, multicenter Phase I trial (NCT04794699) assessing the safety and efficacy of IDE397, a small molecule inhibitor of MAT2A, in patients with solid tumors with MTAP deletions. Initial enrollment included patients with lung, pancreatic and esophagogastric cancer, with the expansion cohort including additional patients with squamous lung and esophageal cancer. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.